2021
DOI: 10.1124/molpharm.121.000278
|View full text |Cite
|
Sign up to set email alerts
|

Regulation of Adrenergic, Serotonin, and Dopamine Receptors to Inhibit Diabetic Retinopathy: Monotherapies versus Combination Therapies

Abstract: bromocriptine (BRM), diabetic retinopathy (DR), dimethyl sulfoxide (DMSO), dose of minimal inhibition of retinal oxidative stress (DMI ox ), doxazosin (DOX), endothelial cells (ECs), G-protein coupled receptors (GPCRs), inducible isoform of nitric oxide synthase (iNOS), intercellular adhesion molecule1 (ICAM1), metoprolol (MTP), phosphate buffered saline (PBS), streptozotocin (STZ), tamsulosin (TAM). wildtype (WT)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 68 publications
(80 reference statements)
0
3
0
Order By: Relevance
“…We were only able to find two studies that point to dopamine as an anti-angiogenic in the retina: a retrospective study showing that age-related macular degeneration was delayed by approximately 8 years in patients who were taking L-DOPA for Parkinson’s disease ( Brilliant et al, 2016 ) and an animal study showing that the dopamine agonist bromocriptine reduces vascular permeability in diabetic mice ( Kern et al, 2021 ). The research presented here suggests that treatments that target dopamine could be used as in the diabetic retina to reduce or prevent neovascularization and other vascular pathology, the clinical hallmark of DR and a cause of blindness.…”
Section: Discussionmentioning
confidence: 99%
“…We were only able to find two studies that point to dopamine as an anti-angiogenic in the retina: a retrospective study showing that age-related macular degeneration was delayed by approximately 8 years in patients who were taking L-DOPA for Parkinson’s disease ( Brilliant et al, 2016 ) and an animal study showing that the dopamine agonist bromocriptine reduces vascular permeability in diabetic mice ( Kern et al, 2021 ). The research presented here suggests that treatments that target dopamine could be used as in the diabetic retina to reduce or prevent neovascularization and other vascular pathology, the clinical hallmark of DR and a cause of blindness.…”
Section: Discussionmentioning
confidence: 99%
“…These conclusions were supported by the following results: (1) TAM reduced a high glucose-induced expression of TNF-α, IL-6, IL-8, MMP-2 and MMP-9; (2) TAM inhibited the expression of VCAM-1 and ICAM-1, and a high glucose-induced expression of fibrosis factors such as COL-1 and TGF-β1; and (3) TAM reduced oxidative stress by inhibiting the generation of ROS, thus preventing the activation of p38. In addition, therapy involving the use of a combination of drugs that regulate G protein couple receptor (GPCR) signaling pathways including TAM was found to beneficially inhibit the development of early diabetic retinopathy [ 44 ] as well as retinal degeneration [ 45 , 46 ], as compared with the use of each drug individually. In the current study, using 2D and 3D cultures of ARPE 19 cells, we were able to successfully evaluate the drug-induced effects of TAM and obtained the following results: TAM significantly altered the distribution of ECM deposits and the energy balance between glycolysis and OXPHOS, and the increased barrier functions in the 2D ARPE 19 monolayers, and large and stiffer 3D ARPE 19 spheroids, and these effects were concentration dependent.…”
Section: Discussionmentioning
confidence: 99%
“…Among these, serotonin is a crucial monoamine neurotransmitter that regulates central neurotransmission and intestinal physiological functions. Given that serotonin levels in patients with proliferative diabetic retinopathy (PDR) are significantly lower than in healthy subjects, and that the incidence of DR is lower in diabetic patients taking serotonin reuptake inhibitors compared to controls, it is possible that gut microbiota influences DR by regulating the production of tryptophan and serotonin ( Kern et al, 2021 ).…”
Section: Function and Application Of Postbiotics In Dr Treatmentmentioning
confidence: 99%